# Nelfinavir in Systemic Lupus Erythematosus

> **NCT02066311** · PHASE2 · TERMINATED · sponsor: **Northwell Health** · enrollment: 15 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Nelfinavir

## Key facts

- **NCT ID:** NCT02066311
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2018-06
- **Final completion:** 2018-06
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Stage 1 terminated 6/1/18 prior to completion of Stage 1 due to low enrollment and efficacy
- **Last updated:** 2020-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02066311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02066311, "Nelfinavir in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT02066311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*